ventilation is poor. The risk of transmission increases when susceptible persons share air for prolonged periods of time with a person who has untreated pulmonary TB.
Infectious droplet nuclei may be inhaled through the nose and mouth, then move down the trachea into the lungs and along the branches of the airways (the bronchi) until they reach the small air sacs ofthe lung (alveoli). Latent TB infection usually begins in the alveoli where tubercle bacilli are initially able to multiply. During the first weeks after infection, tubercle bacilli can spread from the initial location in the lungs (usually in the lower portions), to the lymph nodes in the center of the chest, and then to other parts of the body by way of the bloodstream.
Tubercle bacilli can reach all areas of the body, but frequently travel to areas that are most susceptible to developing disease, such as the upper portions of the lungs, the kidneys, the brain, and bone. Within 2 to 10 weeks, the body's immunologic response to the tubercle bacilli is usually sufficient to prevent further bacterial multiplication and spread. At this point an infected person will usually have a positive skin test.
Not everyone infected develops active TB disease. In the United States, about 90% of infected persons remain infected for life, with no symptoms of TB. But about 5% de-velop active TB disease in the first year or 2 following infection, and another 5% develop active TB disease later in life (this varies with age and immunologic status).
A person infected with the tubercle bacilli without disease, whose immune system prevents further spread, is said to have latent TB infection (CDC, 1992) . A person with latent TB infection without disease: • Cannot infect others; • Is not considered a case of TB; • Usually has a positive reaction to the tuberculin skin test; • Usually has a negative chest x-ray and no clinical symptoms of TB; • Has · the tubercle bacilli in the body, which although contained, remain viable and capable of producing active TB disease at any time.
For those who develop active TB disease, the lungs are the most common site of involvement (in approximately 85% of all cases). But disease may occur at any site in the body, such as the larynx, lymph nodes, brain (causing TB meningitis), kidney, or bones. Miliary TB may occur when a large number of tubercle bacilli enter the bloodstream and are suddenly carried to all parts of the body; a chest x-ray may look as if there are millet seeds scattered throughout the lung.
Conditions associated with a higher risk of latent TB infection progressing to clinically active TB disease include: HIV infection; x-ray evidence of old, untreated TB; substance abuse, especially injecting drug use (IOU); silicosis ; diabetes mellitus; prolonged corticosteroid therapy; immunosuppressive therapy; hematologic and reticuloendothelial disease such as leukemia and Hodgkin's disease; carcinomas of the oropharynx and upper gastrointesti-500 and being 10% or more below ideal body weight (CDC, 1991) .
TB TRANSMISSION IN HIGH RISK POPULATIONS
TB is still prevalent worldwide. An estimated 30% to 60% of adults in developing countries are infected with M tuberculosis. There are also about eight million new cases and three million deaths attributed to this disease each year (CDC, 1992) .
From 1953, when nationwide reporting first began, to 1984, the number of TB cases reported in the United States dropped an average of almost 6% each year. In 1985, this decrease leveled off and in 1986 there was an actual increase, the first since 1953. From 1986 through 1988, the number of cases remained fairly constant. During 1991, 26,283 cases, an 18% increase since 1985, were reported. The Centers for Disease Control and Prevention (CDC) estimates that in the past 7 years there have been 39,000 more cases than would have been expected, had the downward trend of 1980 to 1984 continued. Much of the recent increase is believed to be due to TB among persons with HIV infection (CDC, 1992) .
Although all the reasons are not understood, the poor are disproportionally affected by TB. Persons living in areas with the lowest average household income are eight times more likely to have TB than those living in areas with the highest average household income.
Among all TB cases reported to the CDC in 1991, 70% occurred in racial/ethnic minority populations. African Americans accounted for 36%. Hispanics 20%. Asians 13%. and American Indians and Alaskan natives a little more than 1% (CDC. 1992). Asians are 10 times more likely to develop TB than non-Hispanic whites. The risk for African Americans is eight times greater than for whites, and the risk for Hispanics. American Indians. and Alaskan natives is five times greater than for whites (CDC, 1992) .
The increase in morbidity has been most pronounced in the racial! ethnic and age groups most heavily affected by AIDS. In the 25 to 44 year old age group. from 1985 to 1991, reported TB cases increased by 52%. of which there was a 30% increase among non-Hispanic whites, a 60% increase among African Americans. a 96% increase among Hispanics. and a 24% increase among Asians (CDC, 1992) .
Tuberculosis is increasing among persons born in countries with a high prevalence of TB. Nearly 27% of all TB cases reported to the CDC in 1991 occurred in persons who had immigrated from another country. The percentage of cases that occur in the foreign born has increased steadily since 1985, when 20% of the reported cases occurred in the foreign born (CDC, 1992) .
TB is a major problem in correctional facilities. A CDC study based on cases reported during 1984 and 1985 showed that the incidence of TB in correctional facilities was four times greater than in the population 15 to 64 years of age outside correctional facilities (CDC, 1992) .
TB rates are higher in correctional facilities than in the general population for several reasons. Populations with a high prevalence of latent TB infection, such as African American and Hispanic men, are disproportionately represented in the prison population. An increasing number of correctional facility inmates have HIV infection and are at greater risk of developing active TB disease from an old or new latent TB infection. A large proportion of inmates have a history of IOU, which is a risk factor for TB independent from HIV infection. Finally, crowded prison environments, including buildings with inadequate ventilation, are conducive to the spread of TB.
The homeless are also at increased risk of TB. Data from selected areas show that from 2% to 7% of America's homeless persons have active TB disease, and up to 51% have latent TB infections. Also, in some areas homeless persons may be more likely than the general population to have HIV infection and to be injecting drug users (CDC, 1992) .
THE AMERICANS WITH DISABILITIES ACT (ADA)
Due to the increasing prevalence of those with active TB disease, HIV infection, and AIDS, recent federal legislation under the ADA will present special challenges in the OCTOBER 1994, VOL. 42, NO.1 0
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ART I C L E workplace. Under the ADA, enacted in 1990, an employer cannot discriminate against a qualified individual who has a disability, had a disability, or is perceived to have a disability. A qualified individual with a disability is a person who meets the job requirements (Le., skills, education, work experience), and can perform the essential functions of the job. Essential functions are those primary tasks critical to successful performance of a job. An employer does not have to hire or retain individuals whose disabilities prevent them from performing the essential job functions.
Individuals with latent TB infection are protected by the ADA if an employer discriminates against them on the basis of their TB status. Limiting the job responsibilities of an employee with latent TB infection will violate the ADA, as this employee does not pose a significant risk of transmission to anyone else.
Individuals with active TB disease do pose a direct threat of transmission to others. This fact, however, does not entitle employers to refuse to hire or to fire such individuals. Rather, employers have an obligation under the ADA to provide reasonable accommodation(s) to remove the direct threat. Under appropriate circumstances, employers should consider permitting employees to continue to work at home while undergoing treatment. Employers do not have to provide a specific accommodation if it imposes an undue hardship (significant difficulty or expense) on the employer.
In the case of employees with latent TB infection who do not pose a significant risk to others, it is not necessary to notify coworkers of their latent TB infection. However, if an employee is diagnosed with active TB disease, the employer is obligated to notify the local health department. The public health department should protect the confidentiality of the worker with active TB disease as prescribed by state and local law.
Other workers in the same area or group who may have had similar exposure should receive purified protein derivative (PPD) tests to determine if there is additional evidence of transmission. The contact investigation should extend to possibly exposed clients, if indicated. If the initial PPD test is negative, a second test should be administered 12 weeks after the exposure was terminated, to determine if there was a PPD conversion (CDC, 1993) .
RISK ASSESSMENT
TB control measures for each health care facility should be based on a careful assessment of the risk of TB transmission in that setting and the characteristics of the setting. Therefore, the first step in developing a TB control program should be to conduct an initial assessment (Figure) . The risk assessment should be conducted by a group of qualified personnel for the facility as a whole. The elements of a risk assessment are summarized in Table 1 .
The TB infection control plan is based on the risk assessment, and a written plan should be developed and implemented for each area of the facility. lance data are needed to determine the TB control protocol. TB isolation rooms should be single rooms with special ventilation 502 characteristics appropriate for TB isolation. The length of time required for a person to become non-infectious after starting anti-tuberculosis ther-apy will vary. TB isolation should be discontinued only when the person is on effective therapy, is improving clinically, and the sputum smear is CE ART I C L E negative for acid fast bacilli on 3 consecutive days. Before a client is discharged from the health care facility, the facility's staff and public health authorities should collaborate to ensure continuation of therapy.
DIAGNOSIS OF TUBERCULOSIS (CDC, 1993)
Clients with TB disease may present with a history of persistent cough, weight loss, anorexia, chills, night sweats, and fever. TB skin testing, chest x-ray, sputum stain, and sputum cultures will aid in a diagnosis.
Currently, the only acceptable method for TB skin testing is the Mantoux method using five tuberculin units of purified protein derivative (PPD-S) intradermal injection. The skin test should be placed and read by the employee health services staff Client or health care worker self reading of the PPD should not be accepted.
A two step testing method should be used for the initial pre-placement TB test. Two step testing reduces the probability that a boosted skin test reaction will be interpreted as representing recent infection. If the reaction to the first tuberculin skin test is negative, a second test will be given 1 to 3 weeks later. If the reaction to the second test is positive, it probably represents a boosted reaction. A boosted reaction on the second test would classify the individual as having latent TB infection, not a recent converter, and should be managed accordingly.
Application, administration, reading, and interpretation of the Mantoux skin test should be administered according to the most recent American Thoracic Society (needs refer-OCTOBER 1994, VOL. 42, NO.1 0 ence) and CDC recommendations (reference). Currently, recommendations are intradermal injection of .10 mm of purified protein derivative (PPD-5 tuberculin units) in the dorsal or volar surface of the forearm. A discrete, pale elevation of the skin (a wheal) 6 mm to 10 rom in diameter should be produced. If a wheal does not develop, the PPD must be repeated immediately at another site at least 2 inches from the first injection, or the other forearm.
The reading of the PPD skin test is taken 48 to 72 hours after injection. A positive reaction is an area of induration (palpable hardness) around the injection site. Redness or erythema should not be measured. Induration may be determined by using a ball point pen and drawing it lightly into the area until it stops due CE ART I C L E Routine chest x-rays are not required for asymptomatic, PPD negative health care workers. Health care workers with positive PPD tests should have a chest x-ray as part of the initial evaluation of their PPD test; if negative, repeat chest x-rays are not needed unless symptoms develop that may be suggestive of latent TB infection or active TB disease. Persons with a previously known positive PPD who have been exposed to an infected person do not require a repeat PPD or chest x-ray unless they have symptoms suggestive of TB.
Latent TB infections (positive TB skin test) and active TB disease are both recordable on the OSHA 200 log. A positive skin test for TB even on baseline testing (except preplacement screening) is recordable on the OSHA 200 log because there is a presumption of work relatedness. * All records of employee exposures to *The presumption of work relationship may be rebutted with proof that the employee was infected before his or her employment at the establishment. If an employee's pre-assignment test is positive within 2 weeks ofhis or her start date, the presumption is rebutted by the fact that a workplace exposure could not have caused the infection within a time period shorter than the minimum incubation period.
It however, the positive test results occur after 2 weeks following the employee's start date, the case is presumed work related in the above stated industries (Whitmore, 1994 If an employee's latent TB infection, which has been entered on the OSHA log, progresses to active TB disease during the 5 year maintenance period, the original entry for the infection shall be updated to reflect the new information.
Because it is clinically difficult to determine if active TB disease resulted from the source indicated by the skin test conversion or from subsequent exposures, only one case should be entered to avoid double counting.
BCG VACCINATION
Vaccination with Bacillus of Calmette and Guerin (BCG) vaccine is not recommended for widespread use in the United States because of the low risk of infection in the general population. Also, BCG vaccine has varied in effectiveness in eight major trials from 0% to 76%. However, BCG vaccination is recommended for long term protection of infants and children with negative tuberculin skin tests who are at high risk of continuing exposure to persons with infectious TB and who cannot be placed on long term preventive therapy or who are continuously exposed to persons with isoniazid and rifampin resistant disease.
BCG vaccination also should be considered for tuberculin negative infants and children in groups in which the rate of new infections exceeds 1% per year and for whom the usual treatment and control programs are not effective. These groups include persons without regular access to health care, those for whom health care is culturally or socially unacceptable, and groups who have demonstrated an inability to use existing health care (CDC, 1991a) .
PREVENTIVE THERAPY FOR LATENT TB INFECTION
The appropriate use of preventive therapy is critical to the control and elimination ofTB in the United States. The main purpose of preventive therapy is to prevent latent TB infection from progressing to clinically active TB disease. Therefore, persons with a positive tuberculin skin test (PPD) who do not have clinically active TB disease should be evaluated for preventive therapy. Concurrent to the AIDS epidemic is the continuing dramatic increase in TB.
Because of the possible anergy, PPD skin testing may be falsely negative in persons who are HIV infected. In a multicenter cross sectional screening study, clients with a negative PPD skin test within the past 7 to 28 days were given a second skin test in identical fashion , and a reaction of > 5 mm induration was considered a positive skin test. A positive response to the second PPD skin test denoted the booster effect. The booster phenomenon occurs in HIV infected persons, and a small number of persons with latent TB infection may be identified with a two stage skin test. Therefore, preventive therapy also may be used to prevent initial infection (primary prevention) (CPCRA, 1993 (CDC, 1992) . Despi te its proven effecti veness, preventive ther apy is less widely applied in the United States than it should be. Reports submitted to the Centers for Disease Control and Prevention by TB control programs in states and large cities indicate that less than 60 % of infected contacts of persons with newly diagnosed TB are being started on preventi ve therapy.
In a study to determine why TB is not prevented, investigators found that although three fourths of the persons with TB surveyed had contact with a health care provider within 5 years prior to diagnosis of TB, less than one third of them had been tuberculin skin tested even though many had risk factors for TB. Of the persons who had positive skin tests and other factors placing them at increased risk of disease, only 5% had been offered preventive therapy.
The usual preventive therapy regimen is INH, 10 mglkg of body weight daily for children, up to a maximum adult dose of 300 mg daily. The recommended duration of INH preventive treatment varies from 6 to 12 months of continuous therapy. Twelve months is recommended for persons with HIV infection and other forms of immunosuppression and persons with stable abnormal chest x-rays consistent with past TB. Other infected persons should receive a minimum of 6 continuous months of therapy. It is recommended that children receive 9 months of therapy. For persons at especially high risk of TB whose compliance is questionable, supervised preventive therapy may be indicated. Where resources do not permit supervised daily therapy, INH may be given twice weekly at the dose of 15 mglkg of body weight (CDC, 1992 
TREATMENT OF ACTIVE TB DISEASE
An extremely serious aspect of TB in the United States is the recent increase in multi drug resistant-TB (MDR-TB). Those at high risk for MDR-TB include persons who have been recently exposed to MDR-TB, especially if they are immunocompromised; persons with active TB disease who were non-compliant with treatment; persons with active TB disease who were prescribed ineffective treatment; and persons previously treated for active TB disease (CDC, 1993) .
Because administration of a single drug often leads to the development of a bacterial population resistant to that drug , effective regimens for the treatment of TB must contain multiple drugs to which the organisms are susceptible. When two or more drugs are used simultaneously, each helps prevent the emergence of tubercle bacilli resistant to the others.
When the in vitro susceptibility of a client's isolate is not known, which is generally the case at the beginning of therapy, selecting two agents to which the client's isolate is likely to be susceptible can be difficult. Improper selection of drugs for the treatment of drug resistant TB (i.e., providing only one drug to which most organisms are susceptible) may subsequently result in the development of additional drug resistant organisms.
A four drug regimen with isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and streptomycin (SM) or ethambutol (EMB) is preferred for the initial, empiric treatment of TB. When adherence with the regimen is assured, such as with directly observed therapy (DOT), the four drug regimen is highly effective OCTOBER 1994, VOL. 42, NO. 10 CE ART I C L E even for INH resistant organisms. Based on the prevalence and characteristics of drug resistant organisms, at least 95% of clients will receive an adequate regimen (at least two drugs to which their organisms are susceptible) if this four drug regimen is used at the beginning of therapy. Even with susceptible organisms, sputum conversion is accomplished more rapidly from positive to negative with a four drug regimen than with a three drug regimen of INH, RIp, and PZA. DOT is more easily managed with the four drug regimen, as it can be administered intermittently three times a week from the beginning of therapy. The four drug regimen also can be administered two times a week following a 2 week induction phase of daily therapy (CDC, 1993b) .
Finally, a client who is treated with the four drug regimen, but who defaults therapy, is more likely to be cured and not relapse when compared with a client treated for the same length of time with the three drug regimen .
To avoid the emergence of drug resistant organisms, the Advisory Council for the Elimination of Tuberculosis (ACET) recommends the following approach to beginning therapy for TB: • Susceptibility Testing-performed on first isolate; • Initial Regimen-four drug regimen; • General Principles-ongoing surveillance of drug susceptibility patterns; • Immunosuppressed Clientsselecting the most effective regimen for HIV infected persons; • Treatment of Extrapulmonary TB-regimen same as for pulmonary TB;
• Treatment of Infants and Children-same regimen as recommended for adults; • Treatment of TB During Pregnancy-regimen must be adjusted, as SM may cause congenital deafness; • DOT-method of ensuring adherence, requires community outreach.
Persons with pulmonary or laryngeal TB pose a risk to others while they are infectious: therefore, they should be excluded from work until they are no longer infectious. The same work restrictions applicable for immunocompetent health care workers apply to health care workers with active TB disease and HIV infection or other conditions resulting in severely impaired cell mediated immunity.
Before an employee with active TB disease returns to work, the occupational health service needs to ensure that the worker is receiving adequate therapy, cough is resolved, and there have been three negative consecutive daily sputum AFB smears. The Occupational Health Service should ensure the employee remains on anti-TB therapy for the appropriate time and remains AFB sputum smear negative (CDC, 1993) .
Even if a worker is treated for TB by a private physician, a knowledgeable professional in the occupational health services should be advised confidentially of the diagnosis and should verify the appropriateness of the treatment and monitor symptoms and job duties (CDC, 1993) .
PROMOTING COMPLIANT BEHAVIOR
Consideration should be given to treating all clients with DOT, which can be given on an intermittent schedule. DOT means observation of the client by a health care provider or other responsible person as the client ingests anti-TB medications. DOT can be achieved with daily, twice weekly, or thrice weekly administration of medication.
Many factors help promote compliance. The interval between the time of referral and time of appointment should be kept to a minimum. Waiting time in an office or clinic should be minimized. The hours of office or clinic operations should be convenient for the clients, and the clinic or office should be easily accessible by public transportation or transportation services should be available to clients.
The shortest possible treatment regimen should be used. To minimize the number of pills or capsules taken, combined fixed dose capsules (isoniazid-rifampin) should be used. Features of the client's lifestyle, social support system, and health beliefs should be elicited to help design a treatment strategy tailored to the client's needs.
Client education is vital. Therefore, the health care provider must take the time to explain, in simple language, when the medication should be taken and how much should be taken and must make certain that the explanation has been understood. Written instructions should also be provided. Pictures may be a useful tool for the person who cannot read or write. An interpreter may be required to communicate with those clients whose native language is not the same as that of the health care provider.
An approach that may be useful is to assign a specific health care employee the responsibility for ensuring the education of the client about TB and its treatment and ensuring continuity of therapy and 508 CE ART I C L E follow up for contacts. The health care worker should visit the client within 3 days of the diagnosis to identify contacts and identify possible problems related to compliance with therapy.
RECOGNIZING NONCOMPLIANT BEHAVIOR
Noncompliance with therapy is a major problem in TB treatment. To prevent relapses, TB must be treated for months, longer than many other infectious diseases. On the other hand, symptoms often disappear after a few weeks of therapy, and clients often discontinue therapy at that time. Compliance with preventive therapy is even more difficult to ensure, as persons taking the medication do not have symptoms related to their infection. Furthermore, the concept of taking preventive medication may be unfamiliar or initially unacceptable to many individuals who are infected with TB.
Noncompliance can lead to treatment failure, drug resistance, continuing transmission of infection, increasing disability, and death. To prevent these outcomes, health care providers must learn how to recognize, prevent, and manage noncompliant behavior.
Traditionally, health care providers have attempted to predict compliance based on subjective judgments of behaviors or personality traits. This approach is not reliable. In assessing compliance, the response to therapy is helpful and may be inferred by evaluating whether the client's sputum has converted to negative, chest x-ray has improved (for persons with pulmonary TB), or if the signs and symptoms have disappeared. Clients who fail to keep their appointments and/or refill their prescriptions are, by definition, noncompliant.
Asking about compliance in a nonthreatening manner may also be useful. All of these indirect measures have limitations, and none should be used as the sole method of assessing compliance.
More <direct measures can tell the health care provider whether medications have actually been taken by the client. These measures include the measurement of drug levels or metabolites in a sample of the client's urine. Several simple methods for testing urine for the presence of major anti-TB drugs or their metabolites have been published. A quick glance at a urine sample can detect compliance with taking rifampin as, in most clients, rifampin turns urine orangered. However, factors such as the time the rifampin was taken prior to urination and the individual's rate of drug metabolism can affect the usefulness of the observational test.
MANAGEMENT STRATEGIES FOR NONCOMPLIANT BEHAVIOR
Clients who fail to keep an appointment should be contacted immediately, and the reason for this failure should be elicited. Measures to prevent further absences should be discussed.
Use of incentives and enablers may help restore compliance. Health departments have successfully used incentives such as food and clothes to help previously noncompliant individuals complete therapy. Enablers such as bus tokens and babysitting services may ensure that clients can get to the clinic.
A small but increasing number of individuals remain noncompliant despite the use of all the compliance enhancing methods previously mentioned. Consideration should be given to confining these persons to a hospital or other institution for treatment. The exercise of this option depends on the existence of appropriate laws, cooperative court and law enforcement officials, and the availability of institutional care.
RISK ASSESSMENT AND TB CONTROL
The probability of tuberculosis transmission is a function of the concentration of infectious nuclei in room air and the duration of exposure. Because it is difficult to remove droplet nuclei or dilute their concentration in room air, it is far better to prevent their introduction into air at the source. Case finding and effective TB treatment is the ultimate form of source control. Clients can further assist in source control by covering their mouth and nose when coughing and sneezing. Persons unable to cooperate in covering coughs and sneezes can wear ordinary surgical masks for short periods of time while being transported within institutions (CDC, 1992) .
In addition, persons with symptoms consistent with clinically active infectious TB should be placed in an AFB isolation room before the diagnosis is certain, until there is objective evidence that they are unlikely to be contagious. Air from adjacent rooms and corridors must flow into, not out o(AFB isolation rooms (negative pressure), and exhaust air must not be recirculated to other rooms, but to the outside away from any air intake vent (CDC, 1993) .
Cough producing procedures such as pentamidine aerosol treatments and diagnostic sputum inductions have been associated with TB transmission. Because clinically active TB disease cannot be reliably OCTOBER 1994, VOL. 42, NO.1 0
CE
ART I C L E excluded before each procedure, it is recommended that these procedures be performed in booths or isolation rooms occupied by the client alone. Several complete and partial enclosures marketed for this purpose employ high efficiency particulate air (HEPA) filters to obviate exhausting large volumes of air to the outside. Bronchoscopy is another cough producing procedure which may contribute to TB transmission. If TB is a diagnostic possibility and bronchoscopy is required, it should be performed in a room designed to meet AFB isolation specifications. It should not be performed in an operating room designed with positive air pressure relative to adjacent areas, that is, where air moves from the room into the corridor.
All personnel in bronchoscopy rooms and in rooms where other cough inducing procedures are taking place should wear specialized face masks. The currently recommended mask is known as a disposable particulate respirator (HEPA). These face masks must be NIOSH certified and face fitted with the manufacturer's direction for use and disposal followed explicitly (CDC, 1993) .
VENTILATION
Droplet nuclei remain suspended in the air for long periods of time and are rapidly distributed within the available space by room air currents and the building ventilation system. The concentration of infectious droplet nuclei within a building depends on the rate at which they are introduced by the source case, their volume of distribution within the building, and the rate at which they are removed, inactivated, or diluted by the introduction of outside air.
A highly variable amount of out-side air enters most freestanding homes and older buildings in the United States by infiltration through leaks and open windows. In newer buildings that depend on mechanical ventilation systems, most of the air is recirculated. In such buildings, only a small, variable volume of mixed air is exhausted to the outside and is replaced with an equal volume of outside air (CDC, 1993) . National ventilation standards require enough outside air to assure the comfort of most occupants and to keep the concentration of several common indoor pollutants at acceptable low levels. Unfortunately, a ventilation system may appear to be functioning well, effectively distributing a comfortable volume of cool, dehumidified air throughout a building, but may still be recirculating high concentrations of infectious droplet nuclei. A critical element in assessing the risk of airborne infection, therefore, is the amount of outdoor air ventilation. The current minimum recommended air exchange rate for AFB isolation and treatment rooms is six air exchanges per hour (CDC, 1993) .
SUPPLEMENTAL APPROACHES
In institutions where TB is prevalent, other supplemental approaches may be considered. Three approaches are HEPA filtration, germicidal ultraviolet (UV) irradiation, and worker education. HEPA filters within air ducts are capable of almost completely removing airborne particulates the size of droplet nuclei. However, the benefit of HEPA filtration is limited to cost considerations and the amount of air that can be moved through the filters without unacceptable noise or drafts.
Germicidal UV radiation (254 Nm wavelength) has been shown to inactivate virulent tubercle bacilli under experimental conditions, but its efficacy in reducing transmission in actual practice is unknown. Nevertheless, UV lamps have long been used in hospitals and laboratories. UV lamps can sometimes be fitted into return air ducts, thereby disinfecting air before it is recirculated. Like outside air and HEPA filtered air, however, the ability of duct irradiated air to reduce the concentration of droplet nuclei in a room has practical limitations (CDC, 1992) .
UV air disinfection should not be used as a substitute for standard TB control practices, including source control or ventilation with outside air. It is supplemental intervention, which may be appropriate for rooms where high risk procedures are performed, isolation rooms, intensive care units, emergency rooms, and waiting areas in institutions serving populations at high risk for TB (CDC, 1993) .
CONCLUSION
Occupational health nurses can assist their worksites, employees, and communities by adopting a commitment to keep current on infectious diseases such as M tuberculosis (TB).
Tuberculosis continues to be a major public health problem in many
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ART I C L E areas of the United States. Elimination of this disease requires coordinated efforts of public health agencies, voluntary health associations, health care providers, and community groups. Tuberculosis control is comprised of a variety of activities. The key to preventing TB infection, disability, or death from active TB disease is to consider the possibility of TB in high risk groups, make the diagnosis as quickly as possible, and initiate effective, directly observed drug therapy for persons found to have tuberculosis.
The following is a list of resources to assist health care professionals: 
